Identification of patients at high risk of secondary
extramedullary multiple myeloma development

J 2022

Identification of patients at high risk of secondary extramedullary multiple myeloma development

ŠTORK, Martin; Sabina ŠEVČÍKOVÁ; Jiri MINARIK; Petra KRHOVSKA; Jakub RADOCHA et al.

Základní údaje

Originální název

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Autoři

Vydání

British journal of haematology, England, Wiley-Blackwell, 2022, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.500

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00129658

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

multiple myeloma; extramedullary disease; prognostic factors

Štítky

14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 4. 2022 14:31, Mgr. Tereza Miškechová

Anotace

V originále

Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P < 0 center dot 0001], high lactate dehydrogenase (LDH) levels (>5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P < 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P < 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P < 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.

Návaznosti

NV17-29343A, projekt VaV

Název: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

ŠTORK, Martin; Sabina ŠEVČÍKOVÁ; Jiri MINARIK; Petra KRHOVSKA; Jakub RADOCHA; Lenka POSPISILOVA; Lucie KUBÍNOVÁ; Jiří JARKOVSKÝ; Ivan SPICKA; Jan STRAUB; Petr PAVLICEK; Alexandra JUNGOVA; Tomas JELINEK; Viera SANDECKÁ; Vladimir MAISNAR; Roman HAJEK a Luděk POUR. Identification of patients at high risk of secondary extramedullary multiple myeloma development. British journal of haematology. England: Wiley-Blackwell, 2022, roč. 196, č. 4, s. 954-962. ISSN 0007-1048. Dostupné z: https://doi.org/10.1111/bjh.17925.

@article{1818677,
   author = {Štork, Martin and Ševčíková, Sabina and Minarik, Jiri and Krhovska, Petra and Radocha, Jakub and Pospisilova, Lenka and Kubínová, Lucie and Jarkovský, Jiří and Spicka, Ivan and Straub, Jan and Pavlicek, Petr and Jungova, Alexandra and Jelinek, Tomas and Sandecká, Viera and Maisnar, Vladimir and Hajek, Roman and Pour, Luděk},
   article_location = {England},
   article_number = {4},
   doi = {https://doi.org/10.1111/bjh.17925},
   keywords = {multiple myeloma; extramedullary disease; prognostic factors},
   language = {eng},
   issn = {0007-1048},
   journal = {British journal of haematology},
   title = {Identification of patients at high risk of secondary extramedullary multiple myeloma development},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.17925},
   volume = {196},
   year = {2022}
}

TY  - JOUR
ID  - 1818677
AU  - Štork, Martin - Ševčíková, Sabina - Minarik, Jiri - Krhovska, Petra - Radocha, Jakub - Pospisilova, Lenka - Kubínová, Lucie - Jarkovský, Jiří - Spicka, Ivan - Straub, Jan - Pavlicek, Petr - Jungova, Alexandra - Jelinek, Tomas - Sandecká, Viera - Maisnar, Vladimir - Hajek, Roman - Pour, Luděk
PY  - 2022
TI  - Identification of patients at high risk of secondary extramedullary multiple myeloma development
JF  - British journal of haematology
VL  - 196
IS  - 4
SP  - 954-962
EP  - 954-962
PB  - Wiley-Blackwell
SN  - 00071048
KW  - multiple myeloma
KW  - extramedullary disease
KW  - prognostic factors
UR  - https://onlinelibrary.wiley.com/doi/10.1111/bjh.17925
N2  - Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P < 0 center dot 0001], high lactate dehydrogenase (LDH) levels (>5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P < 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P < 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P < 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.
ER  -

ŠTORK, Martin; Sabina ŠEVČÍKOVÁ; Jiri MINARIK; Petra KRHOVSKA; Jakub RADOCHA; Lenka POSPISILOVA; Lucie KUBÍNOVÁ; Jiří JARKOVSKÝ; Ivan SPICKA; Jan STRAUB; Petr PAVLICEK; Alexandra JUNGOVA; Tomas JELINEK; Viera SANDECKÁ; Vladimir MAISNAR; Roman HAJEK a Luděk POUR. Identification of patients at high risk of secondary extramedullary multiple myeloma development. \textit{British journal of haematology}. England: Wiley-Blackwell, 2022, roč.~196, č.~4, s.~954-962. ISSN~0007-1048. Dostupné z: https://doi.org/10.1111/bjh.17925.

Přehled o publikaci